<DOC>
	<DOC>NCT00609388</DOC>
	<brief_summary>The evaluation of the efficacy of an intraportal infusion with Tacrolimus, at the time of liver graft implantation, compared to a control group without immunosuppressive intraportal infusion (Placebo: Saline solution 0.9%) with respect to the initial liver function measured by the parameters of the liver function (LFP): AST (U/L), ALT (U/L), total Bilirubin (mg/dL) and the coagulation factors: NT (%), PTT (s), INR.</brief_summary>
	<brief_title>Tacrolimus During the Implantation and the Effect on Ischemia-reperfusion Injury in Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Multi organ transplantation or retransplantation ABO incompatible donor organ recipients Patients, who are listed on the liver transplantwaiting list at the Vienna General Hospital and who fulfill the clinical requirements (local allocation) Written informed consent Age &gt; 18 First transplantation Fulminant failure of the liver LiverLiving donor recipients pregnant or nursing women Allergy/Intolerance to antimetabolites, HCO60, EL Cremophor or similar compounds,Steroids or macrolide antibiotics HIVpositive donors or recipients Participants of another clinical study Patient has any form of substance abuse, psychiatric disorder or condition, which, in the opinion of the investigator, may invalidate communication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>